New HCM Guidelines

<p>New HCM Guidelines</p> <p>Guest: Steve R. Ommen, M.D. (<a href='https://twitter.com/SteveOmmen'>@SteveOmmen</a>)</p> <p>Host: Kyle W. Klarich, M.D. (<a href='http://twitter.com/KyleWKlarich'>@KyleWKlarich</a>)</p> <p>The distinguished chair of the writing committee for the AHA/ACC 2020 hypertrophic cardiomyopathy guidelines discusses key points in the evolution of guidelines since 2011.</p> <p>Joining us today to discuss current hypertrophic cardiomyopathy guidelines is Steve R. Ommen, M.D., a cardiologist and the director of the Hypertrophic Cardiomyopathy Clinic at Mayo Clinic in Rochester, Minnesota.</p> <p>Specific topics discussed:</p> <ul><li>Major changes to the guidelines <ul><li>Importance of allowing patients to participate in informed decisions related to their care</li> <li>Advocating for the role of comprehensive hypertrophic cardiomyopathy centers</li> <li>Clarification of screening of children and adolescents</li> <li>Risk stratification for sudden cardiac death</li> <li>Emerging implications for use of septal reduction therapies</li> <li>Healthy lifestyles and exercise risks and benefits</li> <li>Guidelines accessibility on American College of Cardiology and American Heart Association apps</li> </ul> </li> <li>Concept of shared decision making and incorporation of the risk calculator into conversation with the patient</li> <li>Revisions to risk factors for sudden cardiac death</li> <li>Discrepancies with 2014-2015 European Society of Cardiology guidelines</li> <li>Partnership and teamwork between comprehensive hypertrophic cardiomyopathy centers and non-center-based cardiologists</li> <li>Guidelines for screening of adolescents</li> <li>Recommendations for active healthy lifestyles and competitive athletes</li> <li>Cautions regarding patients with hypertrophic cardiomyopathy who develop atrial fibrillation</li> </ul> <p>Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at <a href='https://cveducation.mayo.edu'>https://cveducation.mayo.edu</a> or